5 recruiting, 4 active not recruiting, 1 not yet recruiting, 1 terminated. 7 Phase 1, 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Active not recruiting 3, Recruiting 3, Terminated 1 |
| Phase 2 | 3 | Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Advanced Endometrial Carcinoma: new trials by email Literature Review of Advanced Endometrial Carcinoma trials Research Report on Advanced Endometrial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer Biospecimen Collection, Computed Tomography, Elacestrant - Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma | Phase 2 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 50 | 2026-12-18 | 2026-06-09 |
| Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer Bevacizumab, Biospecimen Collection, Carboplatin - Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 255 | 2026-01-27 | 2026-10-23 |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NKT3964, Paclitaxel, Doxorubicin - Solid Tumor, Advanced Solid Tumor | Phase 1 | Recruiting | NiKang Therapeutics, Inc. | 238 | 2024-09-19 | 2026-10-16 |
| A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NKT3447 - Solid Tumor, Solid Tumor, Adult | Phase 1 | Terminated | NiKang Therapeutics, Inc. | 23 | 2024-02-23 | 2025-09-25 |
| Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers Biopsy Procedure, Biospecimen Collection, Cobimetinib - Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 42 | 2023-09-14 | 2026-10-09 |
| At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment - Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 220 | 2023-08-23 | 2026-04-20 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Atezolizumab, Cabozantinib S-malate, Nab-paclitaxel - Advanced Breast Carcinoma, Advanced Endometrial Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 43 | 2022-04-29 | 2026-07-16 |
| IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel - Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 54 | 2021-09-30 | 2026-10-06 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Cisplatin, Elimusertib, Gemcitabine Hydrochloride - Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 74 | 2021-08-25 | 2026-07-31 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Biopsy Procedure, Biospecimen Collection, Ceralasertib - Advanced Breast Carcinoma, Advanced Colon Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 51 | 2021-08-09 | 2026-09-04 |
| Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate - Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 82 | 2018-04-16 | 2026-09-09 |
Endometrial Neoplasms (9) · Ovarian Neoplasms (5) · Carcinosarcoma (3) · Neoplasm Metastasis (3) · Stomach Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Breast Neoplasms (2) · Fallopian Tube Neoplasms (2) · Small Cell Lung Carcinoma (2) · Uterine Diseases (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Chondrosarcoma (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1)
Neoplasms (11) · Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Genital Diseases (10) · Genital Diseases, Female (10) · Genital Neoplasms, Female (10) · Neoplasms by Site (10) · Urogenital Diseases (10) · Urogenital Neoplasms (10) · Uterine Neoplasms (10) · Uterine Diseases (8) · Neoplasms by Histologic Type (7) · Adnexal Diseases (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6)
Magnetic Resonance Spectroscopy (5) · Specimen Handling (5) · Biopsy (3) · Paclitaxel (3) · Taxes (3) · Bevacizumab (2) · Disulfides (2) · Immunoglobulin G (2) · cabozantinib (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · BAY 1895344 (1) · Carboplatin (1) · Cisplatin (1)
National Cancer Institute (NCI) (5) · M.D. Anderson Cancer Center (2) · NiKang Therapeutics, Inc. (2) · Jonsson Comprehensive Cancer Center (1) · Mayo Clinic (1)
United States (11) · Canada (2) · South Korea (1)
Amanda N Fader (1) · Apostolia M Tsimberidou (1) · Jordyn Silverstein, MD (1) · Joyce F Liu (1) · Kanwal P Raghav (1) · Mamta Parikh (1) · Roxana S. Dronca, MD (1) · Stephanie Lheureux (1) · Timothy A Yap, MD (1)
U10CA180868 (1), UM1CA186644 (1), UM1CA186688 (1), UM1CA186709 (1), UM1CA186717 (1)